# Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

> **NCT00455572** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 71 (actual)

## Conditions studied

- Lung Cancer, Non-Small Cell

## Interventions

- **BIOLOGICAL:** Immunotherapeutic GSK1572932A
- **DRUG:** Cisplatin (CDDP)
- **DRUG:** Vinorelbine
- **PROCEDURE:** Radiotherapy

## Key facts

- **NCT ID:** NCT00455572
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05-11
- **Primary completion:** 2013-08-04
- **Final completion:** 2013-08-08
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Study early termination was due to slow recruitment and difficulties at achieving the required enrolment for the study.
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00455572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00455572, "Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00455572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*